Clinicopathological and Prognostic Value of Gastric Carcinoma Highly Expressed Transcript 1 in Cancer: A Meta-Analysis

Overview

Journal J Oncol

Specialty Oncology

Date 2020 Sep 10

PMID 32908508

Citations 2

Authors

Xi Zhou

Yanghua Fan

Yu He

Anna Mou

Fu Wang

Yong Liu

Zhen Wu

Affiliations

Soon will be listed here.

Abstract

Background: Long noncoding RNA gastric cancer highly expressed transcript 1 (lncRNA GHET1) is often reported to be abnormally expressed in multiple cancers, but the situation is different in different cancers. Therefore, a meta-analysis is necessary to clarify the value of lncRNA GHET1 as a prognostic indicator in cancer.

Methods: Relevant research studies on lncRNA GHET1 and cancer were retrieved from three electronic literature databases of Web of Science, PubMed, and OVID. Meanwhile, hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated to explore the relationship between lncRNA GHET1 expression and survival of cancer patients. The odds ratios (ORs) and 95% CIs were calculated to assess the association of lncRNA GHET1 expression with pathological parameters of cancer patients.

Results: The meta-analysis included a total of 11 studies involving 714 cancer patients. The pooled HR suggests that high lncRNA GHET1 expression is associated with poor overall survival. In addition, high expression of lncRNA GHET1 was found to be associated with larger tumor size, poor histological grade, high tumor stage, lymph node metastasis, and distant metastasis.

Conclusions: High lncRNA GHET1 expression can predict poor survival and pathological parameters. And lncRNA GHET1 could serve as a new indicator in multiple cancers.

Citing Articles

The Value of Dysregulated LncRNAs on Clinicopathology and Survival in Non-Small-Cell Lung : A Systematic Review and Meta-Analysis.

Wang J, Han X, Yuan Y, Gu H, Liao X, Jiang M Front Genet. 2022; 13:821675.

PMID: 35450214 PMC: 9016135. DOI: 10.3389/fgene.2022.821675.

Cervical carcinoma high-expressed long non-coding RNA 1 promotes papillary thyroid carcinoma cell proliferation and invasion.

Shi P, Liu Y, Zhang M, Yang J, Jing S, Yang D Transl Cancer Res. 2022; 10(9):4158-4168.

PMID: 35116712 PMC: 8798921. DOI: 10.21037/tcr-21-1502.

References

Fan Y, Yan T, Chai Y, Jiang Y, Zhu X . Long noncoding RNA HOTTIP as an independent prognostic marker in cancer. Clin Chim Acta. 2017; 482:224-230. DOI: 10.1016/j.cca.2017.07.031. View

Zhang X, Bo P, Liu L, Zhang X, Li J . Overexpression of long non-coding RNA GHET1 promotes the development of multidrug resistance in gastric cancer cells. Biomed Pharmacother. 2017; 92:580-585. DOI: 10.1016/j.biopha.2017.04.111. View

Guan H, Mei Y, Mi Y, Li C, Sun X, Zhao X . Downregulation of lncRNA suppresses growth and metastasis in human osteosarcoma cells. Onco Targets Ther. 2018; 11:4893-4899. PMC: 6098425. DOI: 10.2147/OTT.S170293. View

Argentiero A, De Summa S, Di Fonte R, Iacobazzi R, Porcelli L, Da Via M . Gene Expression Comparison between the Lymph Node-Positive and -Negative Reveals a Peculiar Immune Microenvironment Signature and a Theranostic Role for WNT Targeting in Pancreatic Ductal Adenocarcinoma: A Pilot Study. Cancers (Basel). 2019; 11(7). PMC: 6678707. DOI: 10.3390/cancers11070942. View

Zheng Y, Gao Y, Li X, Si S, Xu H, Qi F . Long non-coding RNA NAP1L6 promotes tumor progression and predicts poor prognosis in prostate cancer by targeting Inhibin-β A. Onco Targets Ther. 2018; 11:4965-4977. PMC: 6103656. DOI: 10.2147/OTT.S163680. View

Fan Y, He Y, Zhou X, Liu Y, Wang F . Meta-analysis of the prognostic value of for cancer patients in China. Cancer Manag Res. 2019; 11:2027-2037. PMC: 6407511. DOI: 10.2147/CMAR.S196071. View

Liu Z, Luo S, Wu M, Huang C, Shi H, Song X . LncRNA GHET1 promotes cervical cancer progression through regulating AKT/mTOR and Wnt/β-catenin signaling pathways. Biosci Rep. 2019; 40(1). PMC: 6944656. DOI: 10.1042/BSR20191265. View

Fan Y, Fang H, Ji C, Xie H, Xiao B, Zhu X . Long noncoding RNA CCAT2 can predict metastasis and poor prognosis: A meta-analysis. Clin Chim Acta. 2017; 466:120-126. DOI: 10.1016/j.cca.2017.01.016. View

Yang W, Shan Z, Zhou X, Peng L, Zhi C, Chai J . Knockdown of lncRNA GHET1 inhibits osteosarcoma cells proliferation, invasion, migration and EMT in vitro and in vivo. Cancer Biomark. 2018; 23(4):589-601. DOI: 10.3233/CBM-181863. View

10.

Porcelli L, Iacobazzi R, Di Fonte R, Serrati S, Intini A, Solimando A . CAFs and TGF-β Signaling Activation by Mast Cells Contribute to Resistance to Gemcitabine/Nabpaclitaxel in Pancreatic Cancer. Cancers (Basel). 2019; 11(3). PMC: 6468868. DOI: 10.3390/cancers11030330. View

11.

Ma P, Guan Q, Xu D, Zhao J, Qin N, Jin B . LncRNA PANDAR as a prognostic marker in Chinese cancer. Clin Chim Acta. 2017; 475:172-177. DOI: 10.1016/j.cca.2017.10.020. View

12.

Qi P, Du X . The long non-coding RNAs, a new cancer diagnostic and therapeutic gold mine. Mod Pathol. 2012; 26(2):155-65. DOI: 10.1038/modpathol.2012.160. View

13.

Li B, Xie D, Zhang H . Long non-coding RNA GHET1 contributes to chemotherapeutic resistance to Gemcitabine in bladder cancer. Cancer Chemother Pharmacol. 2019; 84(1):187-194. DOI: 10.1007/s00280-019-03873-8. View

14.

Fan Y, Ji C, Xu B, Fan H, Cheng Z, Zhu X . Long noncoding RNA activated by TGF-β in human cancers: A meta-analysis. Clin Chim Acta. 2017; 468:10-16. DOI: 10.1016/j.cca.2017.02.001. View

15.

Fan Y, Ye M, Wu L, Lv S, Wu M, Xiao B . Overexpression of miR-98 inhibits cell invasion in glioma cell lines via downregulation of IKKε. Eur Rev Med Pharmacol Sci. 2015; 19(19):3593-604. View

16.

Wei L, Sun J, Zhang N, Zheng Y, Wang X, Lv L . Noncoding RNAs in gastric cancer: implications for drug resistance. Mol Cancer. 2020; 19(1):62. PMC: 7081551. DOI: 10.1186/s12943-020-01185-7. View

17.

Harris A . REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer. 2005; 93(4):385-6. PMC: 2361581. DOI: 10.1038/sj.bjc.6602730. View

18.

Dai W, Tian C, Jin S . Effect of lncRNA ANRIL silencing on anoikis and cell cycle in human glioma via microRNA-203a. Onco Targets Ther. 2018; 11:5103-5109. PMC: 6112811. DOI: 10.2147/OTT.S169809. View

19.

Guan Z, Cao Y, Li Y, Tong W, Zhuo A . Knockdown of lncRNA GHET1 suppresses cell proliferation, invasion and LATS1/YAP pathway in non small cell lung cancer. Cancer Biomark. 2017; 21(3):557-563. DOI: 10.3233/CBM-170431. View

20.

Zhou J, Li X, Wu M, Lin C, Guo Y, Tian B . Knockdown of Long Noncoding RNA GHET1 Inhibits Cell Proliferation and Invasion of Colorectal Cancer. Oncol Res. 2016; 23(6):303-9. PMC: 7838607. DOI: 10.3727/096504016X14567549091305. View